Abstract Library

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report

Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: rectal neuroendocrine tumor, Erdheim-Chester disease.,

#2930 Treatment of the Pinealoma: Experience from a Rare Case

Introduction: Pinealoma is an extremely rare type of neuroendocrine tumor without evidence-based systemic therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: pinealoma, octreotide, interferon.,

#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)

Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, cost-of-illness, somatostatin analogues,

#1842 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).

Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lombard-Bohas V

Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,

Keywords: pNET, targeted therapy,